---
title: "Sanyuan Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 67.3987 million yuan, a decrease of 16.80%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262760805.md"
description: "Sanyuan Biotechnology released its third-quarter report for 2025, with operating revenue of 476 million yuan for the first three quarters, a year-on-year decrease of 7.54%. The net profit attributable to the parent company was 67.3987 million yuan, a year-on-year decline of 16.80%; the net profit after deducting non-recurring gains and losses was 57.1343 million yuan, a year-on-year decrease of 28.11%. The basic earnings per share were 0.34 yuan"
datetime: "2025-10-26T08:53:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262760805.md)
  - [en](https://longbridge.com/en/news/262760805.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262760805.md)
generator: "portal-rs"
---

# Sanyuan Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 67.3987 million yuan, a decrease of 16.80%

According to the Zhitong Finance APP, Sanyuan Biotechnology (301206.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 476 million yuan, a year-on-year decrease of 7.54%. The net profit attributable to shareholders of the listed company was 67.3987 million yuan, a year-on-year decrease of 16.80%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 57.1343 million yuan, a year-on-year decrease of 28.11%. The basic earnings per share were 0.34 yuan

### Related Stocks

- [301206.CN](https://longbridge.com/en/quote/301206.CN.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [Cloud snail-mail service Docmail enters third day stuck in the outbox](https://longbridge.com/en/news/298033318.md)
- [10:17 ETDarkforce™ advances toward FedRAMP High for government deployment](https://longbridge.com/en/news/297666526.md)
- [Canonical shuttering some of its legacy chat channels](https://longbridge.com/en/news/298053823.md)
- [Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk](https://longbridge.com/en/news/297887371.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**